Core Viewpoint - Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for its gastrin-17 assay kit, which is valid until September 11, 2030 [1] Group 1 - The product is named "Gastrin-17 Assay Kit (Magnetic Microparticle Chemiluminescent Immunoassay)" [1] - The kit is designed for the in vitro quantitative measurement of gastrin-17 (G-17) levels in human serum [1]

Core Viewpoint - Jiukang Bio (300406.SZ) has received a medical device registration certificate from the Beijing Drug Administration for its Gastrin-17 assay kit, which is expected to enhance the company's product range and core competitiveness, positively impacting future development, although it will not significantly affect recent production operations and performance [1] Company Summary - The newly acquired medical device registration certificate pertains to the Gastrin-17 assay kit, utilizing magnetic microparticle chemiluminescent immunoassay technology [1] - This development enriches the company's product categories, which is beneficial for strengthening its core competitiveness [1] - The impact on the company's recent production and operational performance is expected to be minimal [1]

Core Viewpoint - The company Jiukang Biotechnology has received a medical device registration certificate from the Beijing Drug Administration for its product, the Gastrin-17 assay kit, which utilizes magnetic microparticle chemiluminescent immunoassay technology [1] Company Summary - Jiukang Biotechnology (300406.SZ) has announced the receipt of a medical device registration certificate [1] - The registered product is the Gastrin-17 assay kit, indicating a focus on diagnostic tools in the healthcare sector [1]

Core Viewpoint - Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for its Gastrin-17 assay kit, indicating a significant advancement in its product offerings in the medical diagnostics sector [1] Company Summary - Jiukang Bio (300406) announced on September 16 that it has obtained a medical device registration certificate for its Gastrin-17 assay kit, which utilizes magnetic microparticle chemiluminescent immunoassay technology [1] - The expected use of the product is for the in vitro quantitative measurement of Gastrin-17 levels in human serum [1]

Core Viewpoint - Jiukang Bio (300406.SZ) has recently received a Medical Device Registration Certificate from the Beijing Drug Administration for its product, the Gastrin-17 Assay Kit (Magnetic Microparticle Chemiluminescent Immunoassay), which enhances the company's product portfolio and core competitiveness, positively impacting future development, although it will not have a significant effect on recent production operations and performance [1] Company Summary - The acquisition of the Medical Device Registration Certificate enriches the company's product categories [1] - The new product is expected to strengthen the company's core competitiveness [1] - The impact on recent production and performance is not expected to be significant [1]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-077 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 特此公告。 北京九强生物技术股份有限公司 董事会 2025年9月16日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 胃泌素 17 测定试剂 盒（磁微粒化学发光 免疫分析法） | 京 械 注 准 20252400812 | Ⅱ | 自批准之日起有效期 至 2030 年 09 月 11 日 | 本试剂盒用于体外定量 测定人血清中胃泌素 17 （G-17）的含量。 | 上述产品医疗器械注册证的取得，丰富了公司产品类别，有利于增强公 司的核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业 绩 ...

Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]

Core Viewpoint - Jiukang Bio (300406) has recently received five invention patent certificates from the National Intellectual Property Administration, indicating a significant advancement in its research and development capabilities [1] Group 1: Patent Details - The patents include "6-phosphogluconate dehydrogenase mutant and its use in preparing detection reagents," "vancomycin detection kit," "preparation method of conjugates," "use of conjugates in preparing phenytoin detection reagents," and "gentamicin detection kit" [1]

北京九强生物技术股份有限公司 关于公司获得发明专利证书的公告 | 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-076 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司"）于近 期收到中华人民共和国国家知识产权局颁发的 5 项专利证书，具体情况如下： 2、本发明涉及万古霉素检测试剂盒。具体而言，本发明的 6- 磷酸葡萄糖 脱氢酶突变体相较于野生型 6- 磷酸葡萄糖脱氢酶包含选自以下的一个突变或 其组合：D306C、D375C、G426C。使用本发明的 6- 磷酸葡萄糖脱氢酶突变体所 制备的检测试剂盒，其特异性强、灵敏度高、操作方便、检测时间短、定量准确， 适合高通量检测。 3、本发明涉及偶联物的制备方法。具体而言，本发明的 6- 磷酸葡萄糖脱 氢酶突变体相较于野生型 6- 磷酸葡萄糖脱氢酶包含选自以下的一个突变或其 组合：D306C、D375C、G426C。使用本发明的 6- ...

Group 1 - The company, Jiukang Biotechnology, announced that the period for triggering the conversion price adjustment condition starts from August 27, 2025, and ends on September 11, 2025 [1] - During this period, the company's stock has had ten trading days where the closing price was below 85% of the current conversion price, which is 14.43 yuan per share from August 27 to September 4, 2025, and 14.18 yuan per share from September 5, 2025 [1] - If the conversion price adjustment condition is triggered, the company will follow the relevant regulations of the Shenzhen Stock Exchange and the provisions of the prospectus for the issuance of convertible bonds to perform subsequent review procedures and information disclosure obligations [1]